中軸型脊椎關節炎市場：按類型、按治療劑、按給藥途徑、按產品類型、按性別、按分銷管道、按最終用戶、按地區

預計 2025 年中軸型脊椎關節炎市場規模為 44.1 億美元，到 2032 年將達到 70.1 億美元，2025 年至 2032 年的複合年成長率為 6.85%。

中軸型脊椎關節炎 (axSpA) 是一種慢性發炎性風濕性疾病，主要影響脊椎和骶髂關節，其特徵是進行性結構損傷、功能障礙以及對患者生活品質的嚴重影響。全球中軸型脊椎關節炎市場涵蓋了全面的治療性介入、診斷工具和管理解決頻譜，旨在應對這種影響全球數百萬人的衰弱性疾病。該市場包括放射學僵直性脊椎炎(AS) 和非放射學腋窩脊椎關節炎 (nr-axSpA)，反映了人們對該疾病分類和進展的不斷理解。由於醫療專業人員和患者意識的提高，以及早期診斷和生物目標的進步，市場正見證顯著的成長勢頭。

腫瘤壞死因子 (TNF) 抑制劑、白細胞介素-17 (IL-17) 抑制劑和新興的Janus激酶 (JAK) 抑制劑是治療的主流，為患者提供改善的症狀管理和潛在的疾病逆轉。不斷增加的醫療保健支出、日益成長的自體免疫疾病盛行率、透過先進的影像技術提高的診斷能力以及強勁的製藥研發活動共同推動著市場擴張，使全球中軸型脊椎關節炎市場成為更廣泛的風濕病治療行業中的一個重要部分。

市場動態

全球中軸型脊椎關節炎市場受多種強勁促進因素驅動，這些因素增強了市場成長前景並帶來了治療進步的機會。疾病盛行率的上升，尤其是在20-40歲年輕族群中，是成長的主要催化劑，因為據估計，全球0.7%的人口患有中軸型脊椎關節炎，這帶來了對有效治療方案的巨大需求。透過先進的影像技術（包括磁振造影造影(MRI) 和專門的生物標記），提高了人們對該疾病的認知並提升了診斷能力，從而能夠早期發現和干涉該疾病，顯著擴大了可治療的患者群體。強大的創新生物製藥和標靶化緩解疾病抗風濕藥物 (tsDMARDs) 產品線，可提供更高的療效和個人化的治療方案，並透過高階定價和改善的患者治療效果推動市場擴張。

然而，由於生物製藥治療費用可能超過每位患者每年5萬美元，市場成長面臨許多限制因素，包括價格敏感型市場供應有限以及全球醫療保健體系的報銷挑戰。新療法嚴格的核准流程，加上繁瑣的臨床試驗要求，可能導致開發時間延長、開發成本上升，可能阻礙新興療法的市場准入。此外，axSpA的診斷複雜，常導致誤診或延誤診斷，阻礙及時啟動治療和市場滲透。儘管如此，新興經濟體醫療基礎設施的不斷擴張、醫療支出的不斷增加，以及經濟高效的生物學名藥作為品牌生技藥品替代品的日益普及，正在創造巨大的機遇，因為它們使先進療法的可及性更加民主化，並有望推動不同地區和經濟領域的市場擴張。

本研究的主要特點

• 本報告對全球腋窩脊椎關節炎市場進行了詳細分析，並提供了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設 2024 年為基準年。
• 它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。
• 它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球中軸型脊椎關節炎市場的主要企業概況。
• 本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
• 本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
• 可以透過用於分析全球中軸型脊椎關節炎市場的各種策略矩陣來促進相關人員的決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章市場動態、法規與趨勢分析

• 市場動態
• 驅動程式
• 限制因素
• 機會
• 影響分析
• 主要進展
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景
• 產業趨勢

4. 2020 年至 2032 年全球中軸型脊椎關節炎市場（按類型）

• 僵直性脊椎炎
• 非放射學中軸型脊椎關節炎

5. 2020 年至 2032 年全球中軸型脊椎關節炎市場（依治療劑分類）

• 非類固醇消炎劑（NSAID）
• 生物緩解疾病抗風濕藥（bDMARDs）
• 傳統 DMARD 藥物
• 其他（如皮質類固醇）

6. 全球中軸型脊椎關節炎市場（依給藥途徑），2020 年至 2032 年

• 口服
• 皮下注射（SC）
• 靜脈輸液

7. 2020 年至 2032 年全球中軸型脊椎關節炎市場（依產品類型）

• 品牌
• 非專利的

8. 2020 年至 2032 年全球中軸型脊椎關節炎市場（依性別分類）

• 女士
• 男性

9. 全球中軸型脊椎關節炎市場（依通路分類），2020 年至 2032 年

• 醫院藥房
• 零售藥局
• 網路藥局

第 10 章。 2020 年至 2032 年全球中軸型脊椎關節炎市場（依最終用戶分類）

• 醫院
• 專科診所
• 門診手術中心
• 復健物理治療中心
• 其他（學術研究機構等）

第 11 章。 2020 年至 2032 年按地區分類的全球中軸型脊椎關節炎市場

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太地區
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東地區
• 非洲
  • 南非
  • 北非
  • 中部非洲

第12章競爭格局

• AbbVie
• Amgen
• Bristol-Myers Squibb
• Janssen Pharmaceuticals
• Novartis
• Pfizer
• Roche
• UCB
• Eli Lilly and Company
• Merck & Co.
• Gilead Sciences
• Sanofi
• Takeda
• Biogen
• Astellas Pharma

第 13 章分析師建議

• 機會
• 分析師觀點
• Coherent Opportunity Map

第14章參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Axial Spondyloarthritis Market is estimated to be valued at USD 4.41 Bn in 2025 and is expected to reach USD 7.01 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.85% from 2025 to 2032.

Axial Spondyloarthritis (axSpA) represents a chronic inflammatory rheumatic disease primarily affecting the spine and sacroiliac joints, characterized by progressive structural damage, functional impairment, and significant impact on patients' quality of life. The global axial spondyloarthritis market encompasses a comprehensive spectrum of therapeutic interventions, diagnostic tools, and management solutions designed to address this debilitating condition that affects millions worldwide. The market includes both ankylosing spondylitis (AS), the radiographic form, and non-radiographic axial spondyloarthritis (nr-axSpA), reflecting the evolving understanding of disease classification and progression. With increasing awareness among healthcare professionals and patients, coupled with advancements in early diagnosis and targeted biologics, the market has witnessed substantial growth momentum.

The therapeutic landscape is dominated by tumor necrosis factor (TNF) inhibitors, interleukin-17 (IL-17) inhibitors, and emerging Janus kinase (JAK) inhibitors, offering patients improved symptom management and disease modification potential. Rising healthcare expenditure, growing prevalence of autoimmune disorders, enhanced diagnostic capabilities through advanced imaging techniques, and robust pharmaceutical research and development activities are collectively driving market expansion, positioning the global axial spondyloarthritis market as a critical segment within the broader rheumatology therapeutics industry.

Market Dynamics

The global axial spondyloarthritis market is propelled by several compelling drivers that collectively enhance market growth prospects and therapeutic advancement opportunities. Increasing disease prevalence, particularly among young adults aged 20-40 years, serves as a primary growth catalyst, with an estimated 0.7% of the global population affected by axSpA, creating substantial demand for effective treatment solutions. Growing awareness and improved diagnostic capabilities through advanced imaging technologies, including magnetic resonance imaging (MRI) and specialized biomarkers, enable earlier disease detection and intervention, expanding the treatable patient population significantly. The robust pipeline of innovative biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) offers enhanced therapeutic efficacy and personalized treatment approaches, driving market expansion through premium pricing and improved patient outcomes.

However, market growth faces notable restraints including high treatment costs associated with biologic therapies, which can exceed USD 50,000 annually per patient, limiting accessibility in price-sensitive markets and creating reimbursement challenges for healthcare systems globally. Stringent regulatory approval processes for new therapeutic agents, coupled with extensive clinical trial requirements, result in prolonged development timelines and increased development costs, potentially hindering market entry for emerging treatments. Additionally, the complex nature of axSpA diagnosis, often involving years of misdiagnosis or delayed diagnosis, creates barriers to timely treatment initiation and market penetration. Nevertheless, significant opportunities emerge through expanding healthcare infrastructure in developing economies, increasing healthcare spending, and growing acceptance of biosimilar medications that offer cost-effective alternatives to branded biologics, potentially democratizing access to advanced treatments and expanding market reach across diverse geographic regions and economic segments.

Key Features of the Study

• This report provides in-depth analysis of the global axial spondyloarthritis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global axial spondyloarthritis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AbbVie, Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Novartis, Pfizer, Roche, UCB, Eli Lilly and Company, Merck & Co., Gilead Sciences, Sanofi, Takeda, Biogen, and Astellas Pharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global axial spondyloarthritis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global axial spondyloarthritis market

Market Segmentation

• Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Ankylosing Spondylitis
  • Non-radiographic Axial Spondyloarthritis
• Therapeutics Insights (Revenue, USD Bn, 2020 - 2032)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Meloxicam
  • Naproxen
  • Celecoxib
  • Diclofenac
  • Others (Indomethacin, etc.)
  • Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
  • TNF inhibitors
  • Adalimumab
  • Infliximab
  • Etanercept
  • Others (Golimumab, etc.)
  • IL-17 inhibitors
  • Secukinumab
  • Ixekizumab
  • Others (Bimekizumab, etc.)
  • JAK inhibitors
  • Tofacitinib
  • Upadacitinib
  • Conventional DMARDs
  • Sulfasalazine
  • Methotrexate
  • Others (Corticosteroids, etc.)
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Subcutaneous (SC) Injections
  • Intravenous (IV) Infusions
• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Branded
  • Generic
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Female
  • Male
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Rehabilitation & physiotherapy centers
  • Others (Academic and Research Institutes, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • Janssen Pharmaceuticals
  • Novartis
  • Pfizer
  • Roche
  • UCB
  • Eli Lilly and Company
  • Merck & Co.
  • Gilead Sciences
  • Sanofi
  • Takeda
  • Biogen
  • Astellas Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Axial Spondyloarthritis Market, By Type
  • Global Axial Spondyloarthritis Market, By Therapeutics
  • Global Axial Spondyloarthritis Market, By Route of Administration
  • Global Axial Spondyloarthritis Market, By Product Type
  • Global Axial Spondyloarthritis Market, By Gender
  • Global Axial Spondyloarthritis Market, By Distribution Channel
  • Global Axial Spondyloarthritis Market, By End User
  • Global Axial Spondyloarthritis Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Axial Spondyloarthritis Market, By Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Ankylosing Spondylitis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Non-radiographic Axial Spondyloarthritis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Axial Spondyloarthritis Market, By Therapeutics, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Meloxicam
      • Naproxen
      • Celecoxib
      • Diclofenac
      • Others (Indomethacin, etc.)
• Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • TNF inhibitors
      • Adalimumab
      • Infliximab
      • Etanercept
      • Others (Golimumab, etc.)
      • IL-17 inhibitors
      • Secukinumab
      • Ixekizumab
      • Others (Bimekizumab, etc.)
      • JAK inhibitors
      • Tofacitinib
      • Upadacitinib
• Conventional DMARDs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • Sulfasalazine
      • Methotrexate
• Others (Corticosteroids, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Axial Spondyloarthritis Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subcutaneous (SC) Injections
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous (IV) Infusions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Axial Spondyloarthritis Market, By Product Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Branded
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Generic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Axial Spondyloarthritis Market, By Gender, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Axial Spondyloarthritis Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Axial Spondyloarthritis Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Rehabilitation & physiotherapy centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Academic and Research Institutes, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Axial Spondyloarthritis Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

12. Competitive Landscape

• AbbVie
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Janssen Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Roche
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• UCB
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gilead Sciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Astellas Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

13. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

14. References and Research Methodology

• References
• Research Methodology
• About us